About mbiomics
mbiomics is a Healthcare company based in Munchen (Germany) founded in 2020. Genomic platforms for microbiome therapeutics development are provided. mbiomics has raised $14.04 million across 2 funding rounds from investors including Bayern Kapital, High-Tech Gründerfonds and MIG Fonds. mbiomics offers products and services including Microbiome Therapeutics and Profiling Technology. Its focus areas include Life Sciences, Genomics, Applied Genomics and Microbial Genomics. Its legal entity is mbiomics GmbH.
Company details
mbiomics was founded in 2020 in Munich, Germany, as a provider in the biotechnology sector focused on microbiome analysis. A genomic-based platform is offered that integrates DNA and RNA sequencing for detecting single molecules in microbial samples. Tools such as GOLD for comprehensive microbiome evaluation, monitors for observing modulation effects, and STRATOS for detailed profiling are included in its operations to support therapeutics development.
- Headquarters Munchen, Germany
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mbiomics.com
- Social LinkedIn
- Legal Name Mbiomics Gmbh
- Total Equity Funding$14.04M (USD)
in 2 rounds
- InvestorsBayern Kapital
& 2 more
Products & Services of mbiomics
mbiomics offers a comprehensive portfolio of products and services, including Microbiome Therapeutics and Profiling Technology.
Develops treatments using microbial communities for chronic diseases.
Analyzes microbiome composition for therapeutic development.
Funding Insights of mbiomics
mbiomics has successfully raised a total of $14.04M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.04M
- Total Rounds 2
- First Round $14.04M
(Mar 2023)
- Investors Count 3
All 2 funding rounds of mbiomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $14.08M | Series A | – | – | MIG Fonds,Bayern Kapital |
| Mar 2023 | $14.04M | Series A | – | Bayern Kapital, MIG Fonds |
3 investors in total: 3 institutional.
Investors in mbiomics
mbiomics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Bayern Kapital, High-Tech Gründerfonds and MIG Fonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
High-tech industries are targeted for investments by Bayern Kapital. | bayernkapital.de | Landshut, Germany | ||
Early-stage investments are made in high-tech startups by HTGF. | htgf.de | Bonn, Germany | ||
Venture capital investments in technology companies are managed by MIG Fonds. | mig-fonds.de | Germany |
Investor details for mbiomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of mbiomics
7 people are tracked at mbiomics (2 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Johannes B. Woehrstein | CTO & Founder | Leadership |
Christopher Weidenmaier | As Chief Scientific Officer | Leadership |
Maxine Parmentier | Technical Assistant | Team |
Marina Santiago | IO Product Lead | Team |
Rafael Cuadrat | Principal Scientist (computational Biology) | Team |
Alexandra Götz | Microbiome Analytics | Team |
Kinga Zielinska | Bioinformatics Scientist | Team |
Complete people profiles for mbiomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of mbiomics
3 dated milestones of mbiomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded mbiomics is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Series A,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mbiomics
Complete news archive for mbiomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about mbiomics
mbiomics was founded in 2020 and raised its 1st funding round 3 years after it was founded.
mbiomics is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
mbiomics is a funded company, having raised a total of $14.04M across 2 funding rounds to date. The company's 1st funding round was a Series A of $14.04M, raised on Mar 2023.
mbiomics was founded in 2020 in Munich, Germany, as a provider in the biotechnology sector focused on microbiome analysis. A genomic-based platform is offered that integrates DNA and RNA sequencing for detecting single molecules in microbial samples. Tools such as GOLD for comprehensive microbiome evaluation, monitors for observing modulation effects, and STRATOS for detailed profiling are included in its operations to support therapeutics development.
mbiomics offers Microbiome Therapeutics and Profiling Technology.
mbiomics has 3 investors. Key investors include Bayern Kapital, High-Tech Gründerfonds, and MIG Fonds.
mbiomics operates through Mbiomics Gmbh.